BLEOMYCIN News

BLEOMYCIN currently has 8 news articles, with 40 predicted indications.

This page combines the AI-predicted indications for BLEOMYCIN with the latest health news. Indications highlighted in orange have recent news coverage.

Drug Information

Evidence level: L5
Predicted indications (40):
- squamous cell carcinoma of penis (99.0%)
- intravascular large B-cell lymphoma (99.0%)
- primary cutaneous diffuse large B-cell lymphoma, Leg type (99.0%)
- mantle cell lymphoma (99.0%)
- T-cell/histiocyte rich large B cell lymphoma (99.0%)
- cervical cancer (99.0%)
- classic Hodgkin lymphoma (99.0%)
- diffuse large B-cell lymphoma (99.0%)
- Hodgkins lymphoma (99.0%)
- penile neoplasm (99.0%)
- adenocarcinoma of penis (99.0%)
- non-Hodgkin lymphoma (99.0%)
- Langerhans cell histiocytosis (99.0%)
- lymphoma (99.0%)
- squamous cell carcinoma (99.0%)
- obsolete Hodgkin's granuloma (99.0%)
- head and neck cancer (99.0%)
- upper aerodigestive tract neoplasm (99.0%)
- plasmablastic lymphoma (99.0%)
- classic Hodgkin lymphoma, lymphocyte-rich type (99.0%)
- cervical carcinoma (99.0%)
- ALK-positive large B-cell lymphoma (99.0%)
- B-cell neoplasm (99.0%)
- Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly (99.0%)
- follicular lymphoma (99.0%)
- cervical carcinosarcoma (99.0%)
- penile cancer (99.0%)
- primary mediastinal large B-cell lymphoma (99.0%)
- Hodgkin's paragranuloma (99.0%)
- diffuse large B-cell lymphoma of the central nervous system (99.0%)
- primary central nervous system lymphoma (99.0%)
- lymphosarcoma (99.0%)
- lymphoma, non-Hodgkin, familial (99.0%)
- neoplasm of mature B-cells (99.0%)
- cauda equina neoplasm (99.3%)
- adult astrocytic tumour (99.3%)
- reticulum cell sarcoma (99.1%)
- primary pulmonary lymphoma (99.1%)
- pulmonary blastoma (99.0%)
- well-differentiated fetal adenocarcinoma of the lung (99.0%)